ArriVent BioPharma, Inc. Cash Flow Statement

Cash Flow Statement Dec2023 Dec2024
Operating Activities
Share-based Compensation 0.90M3.21M
Gains from Investment Securities 0.30M
Cash from Operations -55.84M-70.21M
Change in Working Capital
Change in Account Payables 1.38M-0.75M
Change in Accured Expenses 1.56M6.38M
Other Working Capital Changes -9.67M-1.46M
Investing Activities
Change in Acquisitions & Divestments 25.00M1.70M
Cash from Investing Activities -192.47M
Financing Activities
Other financing activities 2.41M
Cash from Financing Activities 42.86M186.58M
Additional items
Change in Cash -12.98M-76.10M
Free Cash Flow -55.84M-70.21M
Net Cash Flow -12.98M-76.10M